Novel study highlights role of IAPP oligomerisation in type 2 diabetes progression
attyloid is thrilled to share exciting findings from a recent study that explored the role of Islet amyloid polypeptide (IAPP) oligomerisation in the pathology of type 2 diabetes (T2D). Traditionally, IAPP oligomers have been detected in affected tissues, but this study marks the first time their presence in blood plasma has been quantitatively analyzed using attyloid’s sFIDA (surface-based Fluorescence Intensity Distribution Analysis) technology.
The study found that IAPP oligomerisation levels in blood plasma were highest among individuals with T2D who were not undergoing insulin therapy and did not exhibit late-stage complications. In contrast, healthy controls showed the lowest levels of IAPP oligomerisation. Notably, in patients with T2D, higher IAPP oligomerisation levels were linked to longer disease duration, suggesting a correlation between IAPP aggregation and the progression of T2D.
These results bolster the hypothesis that IAPP aggregation may be a driving factor in the development and progression of T2D, rather than merely a consequence of the disease. This challenges the conventional view that T2D development primarily results from insulin resistance leading to pancreatic β-cell exhaustion.
The use of sFIDA technology has proven crucial in unveiling these insights, demonstrating its potential to deepen our understanding of T2D pathology. Further research, including comparative analyses with primary tissues, is needed to solidify these findings and explore the therapeutic potential of targeting IAPP oligomers in T2D management.
Stay connected with attyloid for more updates as we continue to push the boundaries of diabetes research using innovative technologies like sFIDA.